Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer

BACKGROUND: In the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Cascinu, Stefano, Bodoky, György, Muro, Kei, Van Cutsem, Eric, Oh, Sang Cheul, Folprecht, Gunnar, Ananda, Sumitra, Girotto, Gustavo, Wainberg, Zev A., Miron, Maria Luisa Limon, Ajani, Jaffer, Wei, Ran, Liepa, Astra M., Carlesi, Roberto, Emig, Michael, Ohtsu, Atsushi
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2020
Ämnen:
Gastrointestinal Cancer
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930430/
https://ncbi.nlm.nih.gov/pubmed/33274542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13623
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk